Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA

BACKGROUND: A high proportion of patients with relapsing remitting multiple sclerosis convert to secondary progressive multiple sclerosis (SPMS) characterized by irreversibly progressing disability and cognitive decline. Siponimod (Mayzent), a selective sphingosine-1-phosphate receptor modulator, wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Hoffmann, Olaf, Klotz, Luisa, Schreiber, Herbert, Weber, Martin S, Rauser, Benedict
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414415/
https://www.ncbi.nlm.nih.gov/pubmed/32499214
http://dx.doi.org/10.2196/19598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414415/
https://www.ncbi.nlm.nih.gov/pubmed/32499214
http://dx.doi.org/10.2196/19598

Ejemplares similares